By James Streeter, global vice president life sciences product strategy, Oracle
As COVID-19 spread across the globe, life sciences organizations were forced to quickly change their approach to clinical trials. With travel restrictions and lockdowns, physical access to patients became almost impossible. Organizations accelerated their plans to shift to decentralized clinical trial models that leverage remote data collection technologies and processes to engage with patients, rather than in-person visits.
To better understand how organizations are adapting to this new clinical trial environment, Informa Pharma Intelligence and Oracle Health Sciences conducted a survey of biopharmaceutical companies, contract research organizations, and medical device companies involved in clinical trials around the world. The survey’s 252 qualified respondents were mostly from North America and Europe.
Continue reading to learn how this research reveals that COVID-19 has accelerated adoption of decentralized approaches and remote data collection for clinical trials and that this transition that has come with both challenges and benefits.